All In Biotech

Free tool

FAERS Monitor: Hicon

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021305 or its brand name (Hicon, Sodium Iodide I-131). Reports on generic versions are filed under their own applications.

Reports

960

Serious

900

94% of reports

Hospitalization

63

Death reported

46

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • hypothyroidism385
  • endocrine ophthalmopathy36
  • treatment failure26
  • acute myeloid leukaemia24
  • dacryostenosis acquired24
  • hyperthyroidism23
  • parathyroid tumour benign21
  • abortion spontaneous20
  • hyperparathyroidism19
  • lacrimation increased19
  • nausea19
  • breast cancer17
  • maternal exposure during pregnancy17
  • thyroid cancer17
  • sialoadenitis16

Reports by year received

View as table
YearReports
20051
20061
200733
200877
200956
201056
2011263
2012173
201382
201414
201517
201620
20176
201829
201949
202014
202150
20228
20231
20243
20252
20265

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,199 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
endocrine ophthalmopathySignal36948.9683.831,774
parathyroid tumour benignSignal21638.7415.812,381
dacryostenosis acquiredSignal24415.1278.69,328
hypothyroidismSignal385267.4247.3100,834
sialoadenitisSignal16260.3159.73,832
hyperparathyroidismSignal19203.9130.33,602
hyperthyroidismSignal2334.923.3722
acute myeloid leukaemiaSignal2433.822.8731
thyroid cancerSignal1731.019.3463
lacrimation increasedSignal1913.88.8213
abortion spontaneousSignal2010.97.1171
treatment failureSignal266.94.7125
maternal exposure during pregnancySignal174.22.638
breast cancerSignal174.02.535
nausea190.50.38

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.